MicroVision, Inc.
27.4.2022 22:21:08 CEST | ACCESS Newswire | Press release
REDMOND, WA / ACCESSWIRE / April 27, 2022 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced its first quarter 2022 results.
"We made significant progress in the first quarter of 2022. We track tested our integrated Long Range Lidar sensor and perception software, demonstrating promising ground-truth data of our high-fidelity/low-latency solution at speeds of over 60 mph," said Sumit Sharma, MicroVision's Chief Executive Officer. "We continue to receive positive feedback and interest from automotive OEMs and Tier 1 suppliers for our best-in-class product with cost advantages."
"We began our testing in the U.S. and expect to conduct several more rounds of tests of our high-speed Highway Pilot system both in the U.S. and Germany during the second quarter as we work to deliver on our 2022 objectives," continued Sharma.
Key Financial Highlights for Q1 2022
- Revenue for the first quarter of 2022 was $0.4 million, compared to $0.5 million for the first quarter of 2021.
- Net loss for the first quarter of 2022 was $13.2 million, or $0.08 per share, which includes $3.7 million of non-cash, share-based compensation expense, compared to a net loss of $6.2 million, or $0.04 per share, which includes $1.6 million of non-cash, share-based compensation expense, for the first quarter of 2021.
- Adjusted EBITDA for the first quarter of 2022 was negative $9.0 million, compared to negative $4.3 million in the first quarter of 2021.
- Cash used in operations for the first quarter of 2022 was $10.9 million, compared to cash used in operations for the first quarter in 2021 of $4.5 million.
- The Company ended the first quarter of 2022 with $103.3 million in cash and cash equivalents including investment securities, compared to $115.4 million at the end of December 31, 2021.
Conference Call and Webcast: Q1 2022 Results
MicroVision will host a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session at 2:00 PM PT/5:00 PM ET on Wednesday, April 27, 2022 to discuss the financial results and provide a business update. Analysts and investors may pose questions for management during the live webcast on April 27, 2022.
The live webcast and slide presentation can be accessed on the Company's Investor Relations website under the Events tab at https://ir.microvision.com/events. The webcast will be archived on the website for future viewing.
About MicroVision
MicroVision is a pioneering company in MEMS based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms and machine learning software into its proprietary technology to address existing and emerging markets. The Company's integrated approach uses its proprietary technology today to develop automotive lidar sensors and provide solutions for advanced driver-assisted systems (ADAS), leveraging its experience building augmented reality micro-display engines, interactive display modules and consumer lidar modules.
For more information, visit the Company's website at www.microvision.com, on Facebook at www.facebook.com/microvisionincor follow MicroVision on Twitter at @MicroVision.
MicroVision is a trademark of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.
Non-GAAP information
To supplement MicroVision's condensed financial statements presented in accordance with GAAP, the Company presents investors with the non-GAAP financial measure "adjusted EBITDA." Adjusted EBITDA consists of GAAP net income (loss) excluding the impact of the following: interest income and interest expense; income tax expense; depreciation and amortization; and share-based compensation.
MicroVision believes that the presentation of adjusted EBITDA provides important supplemental information to management and investors regarding financial and business trends, provides consistency and comparability with MicroVision's past financial reports, and facilitates comparisons with other companies in the Company's industry, many of which use similar non-GAAP financial measures to supplement their GAAP results. Internally, management uses this non-GAAP measure when evaluating operating performance because the exclusion of the items described above provides an additional useful measure of the Company's operating results and facilitates comparisons of the Company's core operating performance against prior periods and its business objectives. Externally, the Company believes that adjusted EBITDA is useful to investors in their assessment of MicroVision's operating performance and the valuation of the Company.
Adjusted EBITDA is not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of MicroVision's business as determined in accordance with GAAP. The Company expects to continue to incur expenses similar to the non-GAAP adjustments described above, and exclusion of these items from its non-GAAP financial measure should not be construed as an inference that these costs are unusual or infrequent. The Company compensates for limitations of the measure by prominently disclosing GAAP net income (loss), which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation from GAAP net income (loss) to adjusted EBITDA.
MicroVision has included a reconciliation of GAAP net income (loss) to adjusted EBITDA for the relevant periods.
Forward-Looking Statements
Certain statements contained in this release, including the Company's plans regarding product demonstration and product capabilities are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in such forward-looking statements include the risk its ability to operate with limited cash or to raise additional capital when needed; market acceptance of its technologies and products or for products incorporating its technologies; the failure of its commercial partners to perform as expected under its agreements, including from the impact of COVID-19 (coronavirus); its financial and technical resources relative to those of its competitors; its ability to keep up with rapid technological change; government regulation of its technologies; its ability to enforce its intellectual property rights and protect its proprietary technologies; the ability to obtain customers and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market its products; potential product liability claims; its ability to maintain its listing on The Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect the Company. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect the Company to a greater extent than indicated. Except as expressly required by federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.
MicroVision, Inc.
Balance Sheet
(In thousands)
(Unaudited)
| March 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
Assets | ||||||||
Current Assets | ||||||||
Cash and cash equivalents | $ | 55,611 | $ | 82,647 | ||||
Investment securities, available-for-sale | 47,651 | 32,720 | ||||||
Inventory | 1,815 | 1,780 | ||||||
Other current assets | 1,865 | 2,283 | ||||||
Total current assets | 106,942 | 119,430 | ||||||
Property and equipment, net | 3,248 | 3,026 | ||||||
Operating lease right-of-use asset | 5,368 | 5,577 | ||||||
Restricted cash | 1,092 | 1,092 | ||||||
Intangible assets, net | 105 | 115 | ||||||
Other assets | 1,014 | 985 | ||||||
Total assets | $ | 117,769 | $ | 130,225 | ||||
Liabilities and Shareholders' Equity | ||||||||
Current Liabilities | ||||||||
Accounts payable | $ | 1,919 | $ | 3,584 | ||||
Accrued liabilities | 1,288 | 1,170 | ||||||
Contract liabilities | 4,915 | 5,265 | ||||||
Other current liabilities | 474 | 1,181 | ||||||
Current portion of long-term debt | 98 | 392 | ||||||
Current portion of operating lease liability | 686 | 849 | ||||||
Current portion of finance lease obligations | 24 | 21 | ||||||
Total current liabilities | 9,404 | 12,462 | ||||||
Operating lease liability, net of current portion | 4,882 | 4,983 | ||||||
Finance lease obligations, net of current portion | 15 | 26 | ||||||
Total liabilities | 14,301 | 17,471 | ||||||
Commitments and contingencies | ||||||||
Shareholders' Equity | ||||||||
Common stock at par value | 165 | 164 | ||||||
Additional paid-in capital | 746,028 | 742,042 | ||||||
Accumulated other comprehensive loss | (124 | ) | (19 | ) | ||||
Accumulated deficit | (642,601 | ) | (629,433 | ) | ||||
Total shareholders' equity | 103,468 | 112,754 | ||||||
Total liabilities and shareholders' equity | $ | 117,769 | $ | 130,225 | ||||
MicroVision, Inc.
Statement of Operations
(In thousands, except earnings per share data)
(Unaudited)
| Three months ended March 31, | ||||||||
| 2022 | 2021 | |||||||
Product revenue | $ | - | $ | - | ||||
License and royalty revenue | 350 | 479 | ||||||
Total revenue | 350 | 479 | ||||||
Cost of product revenue | 4 | (5 | ) | |||||
Total cost of revenue | 4 | (5 | ) | |||||
Gross margin | 346 | 484 | ||||||
Research and development expense | 7,593 | 4,462 | ||||||
Sales, marketing, general and administrative expense | 5,877 | 2,247 | ||||||
Total operating expenses | 13,470 | 6,709 | ||||||
Loss from operations | (13,124 | ) | (6,225 | ) | ||||
Other expense, net | (44 | ) | (6 | ) | ||||
Net loss | $ | (13,168 | ) | $ | (6,231 | ) | ||
Net loss per share - basic and diluted | $ | (0.08 | ) | $ | (0.04 | ) | ||
Weighted-average shares outstanding - basic and diluted | 164,563 | 155,454 | ||||||
MicroVision, Inc.
Reconciliation of GAAP Net Loss to Non-GAAP Measure
(In thousands, except earnings per share data)
(Unaudited)
| Three months ended March 31, | ||||||||
| 2022 | 2021 | |||||||
GAAP net loss | $ | (13,168 | ) | $ | (6,231 | ) | ||
Add Interest (net) | (31 | ) | 5 | |||||
Add Income taxes | - | - | ||||||
Add Depreciation & amorization | 483 | 299 | ||||||
Add Share-based compensation expense | 3,734 | 1,638 | ||||||
Adjusted EBITDA | $ | (8,982 | ) | $ | (4,289 | ) | ||
Investor Relations Contact
Jeff Christensen and Matt Kreps
Darrow Associates Investor Relations
MVIS@darrowir.com
SOURCE: MicroVision, Inc.
View source version on accesswire.com:
https://www.accesswire.com/699143/MicroVision-Announces-First-Quarter-2022-Results
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
ZAGENO and ORO Labs Partner to Connect Scientific Purchasing with Enterprise Procurement26.8.2026 14:35:00 CEST | Press release
Partnership combines ORO Labs' AI-native procurement orchestration platform with ZAGENO's scientific marketplace and supplier network to deliver a governed, end-to-end purchasing experience for life sciences R&D. BOSTON, MA / ACCESS Newswire / August 26, 2026 / ZAGENO, the scientific procurement platform connecting researchers with 75 million laboratory products from approximately 5,500 suppliers, today announced a strategic partnership with ORO Labs, the AI-native procurement orchestration platform. The partnership connects ORO Labs' enterprise intake, workflow, and approval capabilities with ZAGENO's scientific product discovery, marketplace, supplier network, and fulfillment infrastructure. Together, the companies enable a single governed journey from request and approval through product selection, ordering, and fulfillment. Scientific R&D procurement has specialized requirements. Researchers need fast, intuitive access to highly specific products, while procurement teams need polic
Eudia Accelerates Enterprise AI Transformation with Google Cloud's Gemini Enterprise for Legal25.8.2026 15:50:00 CEST | Press release
PALO ALTO, CA / ACCESS Newswire / August 25, 2026 / Eudia, the augmented intelligence platform for enterprise legal, contracting, and compliance, today announced a partnership with Google to launch new industry-specific AI capabilities on Google Cloud's Gemini Enterprise for Legal. Eudia's agent scales the legal, contracting, and compliance expertise of an organization's top operators to every team in the enterprise. Built on Google's Agent Development Kit and connected via MCP, Eudia combines a suite of specialized agents with digital twins of domain-scoped institutional knowledge, orchestrated with legal-specific reasoning and access to legal databases. Eudia enables Legal, Compliance, Procurement, and Revenue teams to draft and review contracts, analyze marketing assets for compliance, assess risk across thousands of executed contracts, and manage obligations across the entire company portfolio, giving large enterprises a faster path to trusted, governed legal AI. In practice, this
Envision Pharma Group Names Ryan Tubbs, Senior Vice President, Commercial Growth25.8.2026 15:00:00 CEST | Press release
New role unifies sales enablement, lead generation, and marketing under centralized leadership and expands oversight to customer success, supporting a consistent, connected client experience across Envision. FAIRFIELD, CT / ACCESS Newswire / August 25, 2026 / Envision Pharma Group (Envision) has appointed Ryan Tubbs as Senior Vice President, Commercial Growth. In this newly created role, Tubbs will lead the centralized Commercial Growth function spanning sales enablement, lead generation, marketing, and client success. He will also help shape Envision's commercial strategy and operating model to accelerate enterprise growth. Tubbs' remit also includes the Client Implementation and Client Experience teams. Connecting Envision's pre-sale and post-sale capabilities will create a more integrated commercial engine, making it easier for teams to bring the best of Envision to clients and for clients to realize value quickly. The timing is notable as Envision's iEnvision®, market access, and m
Polaris Renewable Energy Announces Renewal of Normal Course Issuer Bid25.8.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / August 25, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") today announced that the Toronto Stock Exchange ("TSX") has accepted its notice of intention to renew its normal course issuer bid ("NCIB"). The Company's Board of Directors believes that an NCIB represents an appropriate and desirable use of its available free cash to increase shareholder value and is in the best interest of the Company and its shareholders. Pursuant to the notice, Polaris may purchase up to 2,021,205 of its common shares ("Shares"), representing approximately 10% of the public float of 20,212,059 Shares as at August 13, 2026, during the twelve month period commencing August 27, 2026 and ending August 26, 2027, provided that the board of directors of Polaris has initially limited the NCIB to repurchase up to 176,872 Shares. As at August 13, 2026, there were 20,895,285 Shares issued and outstanding. Under the NCIB, other than purchases made under block
IXOPAY Appoints Ajoy Krishnamoorthy as CEO to Accelerate Growth and Advance Payments for the Agentic Age25.8.2026 12:00:00 CEST | Press release
Enterprise Software and Commerce Leader Will Guide IXOPAY's Next Development Phase of Its Unified, AI-Native Payments Infrastructure Platform DALLAS, TX / ACCESS Newswire / August 25, 2026 / IXOPAY, the payment infrastructure solution that enables fluid commerce, today announced the appointment of Ajoy Krishnamoorthy as CEO. Krishnamoorthy brings more than two decades of enterprise software leadership and extensive product engineering experience turning complex technologies into platforms that businesses depend on to grow. Krishnamoorthy joins IXOPAY at a pivotal moment, as it helps unlock fluid commerce for enterprise merchants. Krishnamoorthy will focus on bringing IXOPAY's modular product suite into the agentic age, providing merchants with the freedom to buy what they need and build what they want in scaling their global payment operations. He comes with a customer-first mindset, ensuring momentum is maintained, and support is given to customers during this seismic shift in the lan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
